Digbi Health Unifies Midlife Care on Single Telehealth Platform

MOUNTAIN VIEW, Calif., Oct. 02, 2026 /CourierPR/ -- Digbi Health, a precision biology care company, has expanded its platform to include hormone replacement therapy (HRT), unifying obesity, metabolic, gastrointestinal (GI), and inflammatory care on a single telehealth platform. This move comes as more than 300 employers and health plans that contract with Digbi can now offer these new services under their existing agreements, with many already integrating them into their 2027 plan designs.

The expansion allows women to access advanced midlife care and receive GLP-1 and HRT prescriptions through a single app and one clinical team. Personalized nutrition and lifestyle care are tailored to each woman's genetics, gut microbiome, continuous glucose data, and advanced blood biomarkers. This comprehensive approach aims to address the complex health needs of women during menopause, including weight management, glucose control, and gastrointestinal health.

The company's approach is based on the observation that 75% of women aged 40 to 60 in Digbi's member population also have an obesity, cardiometabolic, or gastrointestinal diagnosis. By unifying care on a single platform, Digbi Health aims to provide a more holistic and efficient approach to midlife care.

Digbi Health's Precision Biology platform now integrates gut microbiome, genetic, and advanced blood-biomarker testing to personalize HRT care. The company has expanded its genetic and gut microbiome panels to encompass the timing and severity of menopause, using polygenic markers associated with the age of natural menopause and gut microbial signatures linked to estrogen metabolism. These panels are designed to help clinicians predict the onset of a patient's transition, assess its potential severity, and identify interventions that align with her biological predispositions.

The platform is also designed to identify and address risks to bone and cardiovascular health after menopause, the two areas where evidence for hormone therapy is strongest and where lifestyle treatment measurably improves outcomes. By unifying care on a single platform, employers can significantly reduce digital health spend by eliminating separate per-employee fees for a standalone menopause program.

A peer-reviewed actuarial claims analysis across seven self-insured employers documented a $3,012 reduction in total healthcare expenditures per member per year. This figure underscores the potential cost savings for employers and health plans by consolidating previously separate obesity, metabolic, and gastrointestinal programs onto the platform.

In conclusion, Digbi Health's expansion into HRT and the unification of care on a single platform represent a significant step in providing comprehensive and personalized midlife care. By addressing the interconnected health needs of women, the company aims to improve health outcomes and reduce overall healthcare costs.